Clinical Pharmacology and Toxicology Unit, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel; affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Autistic Spectrum Disorder Clinic, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel; affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Cannabis Cannabinoid Res. 2024 Feb;9(1):293-299. doi: 10.1089/can.2022.0112. Epub 2022 Nov 7.
Tourette's syndrome (TS) is a neurodevelopmental disorder characterized by vocal and motor tics and other comorbidities. Clinical recommendations for the use of medical cannabis are established, yet further guidance is needed. The aim of this study was to describe the experience of patients with TS with medical cannabis. TS patients were recruited from a registry of patients ("Tikun Olam" company). Questionnaires were answered before and after 6 months of treatment. Patients were divided into two groups: (A) patients who responded and (B) patients who did not respond to the follow-up questionnaire. In group A, an analysis was made to evaluate the presence and frequency of motor and vocal tics. The patients' general mood, employment status, quality of life, and comorbidities were also included in the analysis. Seventy patients were identified. The tetrahydrocannabinol and cannabidiol mean daily dose was 123 and 50.5 mg, respectively. In group A, a statistically significant improvement was identified in quality of life (<0.005), employment status (=0.027), and in the reduction of the number of medications (<0.005). Sixty-seven percent and 89% of patients with obsessive-compulsive disorder and anxiety comorbidities, respectively, reported an improvement. No statistically significant improvement was identified in motor tics (=0.375), vocal tics (>0.999), tics frequency (=0.062), or general mood (=0.129). The most frequent adverse effects were dizziness (=4) and increased appetite (=3). Subjective reports from TS patients suggest that medical cannabis may improve their quality of life and comorbidities. More studies are needed to evaluate the efficacy and safety of medical cannabis. Registry in the MOH: https://www.moh.gov.sg/ (Trial number: 0185-19-ASF).
妥瑞氏症候群（TS）是一种神经发育障碍，其特征为发声和运动抽搐以及其他合并症。已经制定了使用医用大麻的临床建议，但需要进一步的指导。本研究的目的是描述患有 TS 的患者使用医用大麻的经验。TS 患者从患者登记处（“Tkoun Olam”公司）招募。在治疗 6 个月前后回答了问卷。患者分为两组：（A）对随访问卷有反应的患者和（B）无反应的患者。在 A 组中，进行了分析以评估运动和发声抽搐的存在和频率。还分析了患者的一般情绪、就业状况、生活质量和合并症。 确定了 70 名患者。四氢大麻酚和大麻二酚的平均日剂量分别为 123 和 50.5mg。在 A 组中，生活质量（<0.005）、就业状况（=0.027）和减少药物数量（<0.005）方面均有统计学显著改善。分别有 67%和 89%的强迫症和焦虑症合并症患者报告病情改善。运动抽搐（=0.375）、发声抽搐（>0.999）、抽搐频率（=0.062）或一般情绪（=0.129）无统计学显著改善。最常见的不良反应是头晕（=4）和食欲增加（=3）。TS 患者的主观报告表明，医用大麻可能改善他们的生活质量和合并症。需要更多的研究来评估医用大麻的疗效和安全性。在 MOH 注册：https://www.moh.gov.sg/（试验编号：0185-19-ASF）。
